abatacept 
GtoPdb Ligand ID: 6891
|
Synonyms: BMS-188667 | CTLA4-IgG4m | Orencia® | RG-1046 | RG-2077
abatacept is an approved drug (FDA (2005), EMA (2005))
Compound class:
Peptide or derivative
Comment: Abatacept is a recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1) [3]. In essence, abatacept is a CTLA-4 mimetic, that enhances CTLA-4's inhibitory signal to T cells, thereby down-modulating T cell mediated inflammation.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖
View more information in the IUPHAR Pharmacology Education Project: abatacept |
| Immunopharmacology Comments |
| Abatacept is a selective T cell costimulation modulator used in inflammatory autoimmune diseases, that promotes the coinhibitory activity of the immune checkpoint CTLA-4-CD86/CD80 on T cell activation. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
Approved drug for PsA. | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Approved drug for RA. | |
| Juvenile idiopathic arthritis- systemic |
OMIM:
604302 |
Approved drug for JIA. | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License